Science & Technology: The Evolution of Oncologic Drug Development

Posted 01 January 2009 | By

Despite a doubling in the number of candidates in the cancer drug pipeline from 1990 through 2006, the overall US approval rate for cancer drugs remains low (8%).1


Regulatory Focus newsletters

All the biggest regulatory news and happenings.